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Background: Gami-Cheongyeul-Sodok-Eum (GCSE), an herbal formula of traditional Korean medicine, comprises
nine herb components. GCSE has various biological activities such as anti-inflammatory, anti-bacterial and anti-viral
activities. However, it is still unclear whether GCSE has any immunomodulatory effect on atopic dermatitis (AD).
Methods: GCSE was treated to primary B cells and CD4+ T cells isolated from atopic mice to compare its inhibitory
effects on IgE secretion and cytokine expression. Experimental AD was established by alternative treatment of
2, 4-dinitrochlorobenzene (DNCB) and house dust mite extract to the ears of BALB/c mice. GCSE was topically
applied to ears of atopic mice every day for 3 weeks. AD progression was analyzed by measuring ear thickness,
serum IgE level, histological examination of ear tissue by H&E staining and cytokine profile of CD4+ T cells and
CD19+ B cells by real time PCR and ELISA.
Results: Treatment of GCSE significantly reduced IgE production and expression of AD associated pathogenic
cytokines such as IL-4, IL-5, IL-10, IL-13, IL-17, TNF-α, and IFN-γ by lymphocytes isolated from AD-induced mice.
Topical application of GCSE on the ears of AD-induced mice significantly reduced ear thickness, clinical score and
lymphocytes infiltration to ears as compared to control group. GCSE treatment also reduced serum IgE level and
the levels of major pathogenic cytokines such as IL-4, IL-5, IL-10, IL-13 and IL-17. In addition, GCSE treatment
significantly increased Foxp3 expression level.
Conclusions: The protective effect of GCSE in experimental AD is mediated by inhibition of IgE production, by
reduction in the levels of pathogenic cytokines and by induction of Foxp3, all of which are suggesting the
beneficial effect of GCSE on modulating atopic dermatitis.
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IgE and CytokinesBackground
Atopic dermatitis (AD) is a chronic relapsing skin dis-
ease that is manifested by Th2 dominant hyperimmune
disorder, the incidence of which has rapidly increased
especially in the industrialized countries [1,2]. AD is
caused by complex pathogenic factors including genetic
susceptibility, host’s environment, skin barrier dysfunc-
tion, bacterial infection and immunological factors [3,4].
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stated.pruritus, dryness and inflammation [1,5], which are me-
diated by Th1 and Th2 immune responses. Th2 cells
produce IL-4, IL-5, and IL-13 and play major roles in
acute atopic dermatitis [6-8]. Enhanced circulating IgE
levels in AD patients are mainly caused by increased
production of IL-4 and IL-13 [9,10]. In the later stage of
AD where infection mediated inflammation occurs, Th1-
type cytokines such as IFN-γ, and IL-12 mediate the
chronic symptoms of atopic dermatitis [11-13]. Associ-
ation of both Th1 and Th2 immune response in AD
pathogenesis makes it hard to successfully treat AD pa-
tients. Although topical steroid therapy using cortico-
steroid or calcineurin inhibitor is widely used for AD
treatment, it has diverse side effects. Recently, natural
herbs or oriental medicines are employed as newLtd. This is an Open Access article distributed under the terms of the Creative
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disease-modifying efficacy with less side effects [14,15].
Gami-Cheongyeul-Sodok-Eum (GCSE) is a modified for-
mula of Cheongyeul-Sodok-Eum that has anti-inflammatory
and anti-allergic effects [16,17]. GCSE is a mixture of nine
kinds of oriental medicine extracts comprising of Angelicae
Gigantis Radix, Astragali Radix, Atractylodis Rhizoma Alba,
Coptidis Rhizoma, Forsythiae Fructus, Glycyrrhizae Radix,
Lonicerae Flos, Portulacae Herba and Scutellariae Radix.
Angelicae Gigantis Radix exhibits the anti-inflammatory
function through the inhibition of NFκB dependent pro-
inflammatory cytokine expression [18]. Decursin, a major
component of Angelicae Gigantis Radix, modulates inflam-
mation by inhibiting NFκB-Cox-2-PGE2 mediated pathways
[19]. Arctigenin, a bioactive agent of Forsythiae Fructus, has
anti-inflammatory action through the inhibition of leuko-
cytes exudation and recruitment into the inflamed tissues.
Extract of Astragali Radix has anti-inflammatory effect by
inhibiting the activation of p38 and Erk1/2 and NFκB-
mediated transcription [20]. However, no investigation has
been performed to evaluate the AD modifying activity of
GCSE especially upon topical application.
In the present study, we examined the therapeutic
effects of GCSE on experimental AD and elucidated
its action mechanism. In vitro treatment of GCSE to
the lymphocytes isolated from AD-induced mice sup-
pressed IgE production and significantly reduced the
levels of pathogenic cytokines. In addition, topical ap-
plication of GCSE to the mice with ongoing atopic
dermatitis significantly suppressed AD progression by
down-regulating the levels of pathogenic cytokines and
serum IgE levels.
Methods
Standardization of Gami-Cheongyeul-Sodok-Eum (GCSE)
The preparation of Gami-Cheongyeul-Sodok-Eum (GCSE)
was performed in compliance with the test guidelines of
the Korea Food and Drug Administration (KFDA). The
GCSE was prepared as described in Table 1. The 9 herbs
used in the GCSE were purchased from Gwang Myung
Dang Pharmaceutical Company (Ulsan, Korea), identified
by Prof. Bu, Department of Oriental Medicine, Kyunghee
University, and were authenticated by the Jeonnam Trad-
itional Korean Medical Institute (Jangheung, Korea) based
on the Korean pharmacopoeia guidelines. All herbal
voucher specimens (2010-GCSE-01 ~GCSE-09) in GCSE
were deposited at the Department of Herbal Pharmaceut-
ical Development (Nambu University, Gwangju, Korea).
They were ground into powder (135.0 g, 80 mesh), and
were extracted with 1,350 mL of 70% aqueous ethanol at
80°C. The crude extract was concentrated and lyophilized
in vacuo. The weight of the final GCSE extract was
approximately 29.6 g (21.9% of the starting raw herbs).
Each herb was tested for heavy metal (Hg, As, Cd)contamination, residual insecticides, and microbial limit
including LPS contamination. All the materials under
study are endotoxin-free. Standardization of each herb ex-
tract was performed by high performance liquid chroma-
tography (HPLC) analysis. The content of marker
substances in herb extract was compared with commer-
cially available indicator chemicals; glycyrrhizin, liquiriti-
genin, baicalin, baicalein, wogonin and berberine from
Wako Pure Chemical Industries, Ltd. (Osaka, Japan);
decursin and nodakenin from Korea Food and Drug
Administration (KFDA, Seoul, Korea). Other chemi-
cals were of analytical grade. A Shimadzu LC 20 AD
(Shimadzu, Japan) consisting of quaternary solvent
blending, Sil 20A autosampler, column heater, and
SHIMADZU SPD-M20A diode array detector was used
to perform HPLC analysis. The dried GCSE was kept
at 4°C before use.
Cytotoxicity examination by WST-1 assay
Cytotoxicity of GCSE was conducted using EZ-Cytox
cell viability assay kit (Daeil Lab Service Co, Korea). The
manufacturer’s protocol was followed. In summary, 5 ×
103 cells/well isolated from spleen were dispensed in a
96-well plate and incubated for 24 hrs. Various concen-
trations of GCSE, dissolved in 70% ethanol, were treated
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were incubated with 10 μl of the same reagent for 4 hrs.
Using the microplate reader, the absorbance of the soup
was measured at 450 nm. Data were presented by rela-
tive growth inhibition to GCSE non-treated cells.
Animals and Induction of atopic dermatitis
Female BALB/c mice (6–8 weeks) were purchased from
SLC Inc. (Hamamatsu, Japan) and female Foxp3-GFP
knock in mice (6–8 weeks) were purchased from The
Jackson Laboratory (CA, USA). Mice were housed in
specific pathogen-free barrier facility. All experimental
procedures were performed in accordance with the
Guidelines of National Animal Welfare Law of Korea for
the care and use of laboratory animals and were ap-
proved by Animal Care and Ethics Committees of the
Gwangju Institute of Science and Technology (GIST)
(permit number: GIST-2011-3). Induction of experimen-
tal atopic dermatitis was performed as previously de-
scribed [21]. The surfaces of both ear lobes of mice were
stripped with surgical tape (Nichiban, Tokyo, Japan).
After stripping, 20 μl of 2% 2, 4-dinitrochlorobenzene
(DNCB) (Sigma Aldrich, St Louis, MO, USA) dissolved
in acetone/olive oil solution (acetone: olive oil = 1:3) was
painted on each ear. After 3 days, 150 μg of mite extract
(Dermatophagoides farinae, GREER source materials,
Lenoir, NC, USA) dissolved in PBS containing 0.5%
tween 20, was re-painted on ears of mouse. Challenge of
DNCB and mite extract was alternately repeated once a
week for 6 weeks. After 3 weeks of AD induction, mice
were divided into three groups based on similarity of
AD severity clinical scores. Then, mice in each group
were painted daily with 70% ethanol (Cont), GCSE-
2 mg, or GCSE-10 mg on both ears for additional
3 weeks while continuously inducing atopic dermatitis.
Measurement of ear swelling
Ear thickness was measured 24 hrs after application of
DNCB or mite extract with a dial thickness gauge (Kori Seiki
MFG, Co., LTD., Japan). A representative mouse of each
group was photographed to show the clinical symptoms.
Histological examination
Excised ears of each group were fixed in 4% paraformal-
dehyde for 16 hrs and were embedded in paraffin. Then,
6 μm sections were stained with hematoxylin (Sigma
Aldrich, St. Louis, MO, USA) and eosin (Sigma Aldrich,
St. Louis, MO, USA) (H&E). Infiltrating lymphocytes,
thickening of the epidermis, and fibrosis in the dermis
were observed by microscope (50X, 100X, 200X).
ELISA
Total IgE levels in the serum were measured using sandwich
ELISA kit (BD Biosciences) following the manufacturer’sprotocol. For the detection of IgE production from B cells,
CD19+ B cells isolated from AD-induced mice were treated
with diverse concentrations of GCSE, and IgE levels were
measured by ELISA (BD Biosciences, San Diego, CA, USA).
For the detection of cytokine concentration (IL-4, IL-10, IL-
17, and IFN-γ) in the culture supernatant, ELISA was per-
formed by using ELISA kits (e-bioscience, San Diego, CA,
USA).
Isolation of primary CD4+ T cells and CD19+ B cells
Draining lymph nodes (superficial cervical, axillary, and
brachial lymph nodes) from mice were ground using cell
strainer (BD Biosciences, San Diego, CA, USA). CD19+ B
cells or CD4+ T cells were isolated using magnetic beads
(Miltenyi Biotech, Germany) according to the manufac-
turer’s protocol [21,22].
RNA isolation, quantitative RT-PCR (qRT-PCR)
For the cytokine analysis, 3 x 106 cells of CD4+ T cells
or CD19+ B cells from each group were stimulated with
PMA (50 ng/ml)/ionomycin (1 μM) and LPS/IL-4
(10 μg/ml) for 4 hrs, respectively. Total RNA was
extracted from stimulated cells with TRIzol reagent
(Molecular Research Center, Cincinnati, OH, USA) ac-
cording to manufacturer’s protocol. For reverse tran-
scription, 1 μg of total RNA was used. To generate
cDNA, oligo (dT) primer (Promega, Madison, WI, USA)
and Improm-II reverse transcriptase (Promega, Madison,
WI, USA) with a total volume of 20 μl were used. The
mRNA level was determined using 1 μl of cDNA by real
time PCR with SYBR using a protocol provided by the
manufacturer (MJ research chromo4). Mouse HPRT pri-
mer was used for qRT-PCR to normalize the amount of
cDNA used for each condition. PCR was performed with
the following primers: HPRT (Forward - 5’ TTA TGG
ACA GGA CTG AAA GAC 3’, Reverse - 5’ GCT TTA
ATG TAA TCC AGC AGG T 3’); IL-4 (Forward - 5’
ACA GGA GAA GGG ACG CCA T 3’, Reverse - 5’
GAA GCC GTA CAG ACG AGC TCA 3’); IL-5 (For-
ward - 5’ AGC ACA GTG GTG AAA GAG AC 3’, Re-
verse - 5’ TCC AAT GCA TAG CTG GTG ATT T 3’);
IL-10 (Forward - 5’ ATA ACT GCA CCC ACT CCC A
3’, Reverse - 5’ TCA TTT CCG ATA AGG CTT GG 3’);
IL-13 (Forward - 5’ GCA ACA TCA CAC AGG ACC
AGA 3’, Reverse - 5’ GTC AGG GAA TCC AGG GCT
AC 3’); IL-17A (Forward - 5’ TTC ATC TGT GTC TCT
GAT GCT 3’, Reverse - 5’ TTG ACC TTC ACA TTC
TGG AG 3’); IFN-γ (Forward - 5’ GAG CCA GAT TAT
CTC TTT CTA CC 3’, Reverse - 5’ GTT GTT GAC
CTC AAA CTT GG 3’); TNF-α (Forward - 5’ CCC TCA
CAC TCA GAT CAT CTT CT 3’, Reverse - 5’ GCT
ACG ACG TGG GCT ACA G 3’); Foxp3 (Forward - 5’
TTC CTT CCC AGA GTT CTT CC 3’, Reverse - 5’
CTC AAA TTC ATC TAC GGT CCA 3’).
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The isolated primary cells were cultured in RPMI 1640
medium (Welgene, Daegu, Korea) supplemented with 10%
fetal bovine serum (Hyclone, USA), 3 mM L-glutamine
(Sigma Aldrich, St Louis, MO, USA), 100 U/ml penicillin
(Sigma Aldrich, St. Louis, MO, USA), 100 U/ml strepto-
mycin (Sigma Aldrich, St. Louis, MO, USA), non-essential
amino acids (Welgene, Daegu, Korea), sodium pyruvate
(Welgene, Daegu, Korea), HEPES (Welgene, Daegu,
Korea) and 0.05 mM 2-beta-mercaptoethanol (Sigma
Aldrich, St Louis, MO, USA). For the cytokine analysis
in AD experiments, cells were stimulated with PMA
(50 ng/ml) and ionomycin (1 μM) or LPS (10 μg/ml) for
4 hrs. In order to perform the ELISA, cells were stimu-
lated with LPS (10 μg/ml)/IL-4 (5 ng/ml) for 72 hrs.
In vitro iTreg generation
CD4+ T cells isolated from the spleen and lymph node
of 8 weeks old Foxp3-GFP knock-in mice were stimu-
lated in a medium supplemented with anti-CD3 (1 μg/
ml) / CD28 Ab (3 μg/ml), anti-IL-4 Ab (10 μg/ml), anti-
IFN-γ Ab (10 μg/ml), and TGF-β (5 ng/ml) at day 1 and
additional 50 U/ml of rhIL-2 at day 3. Then, iTreg cells
were stimulated with various concentrations of GCSE in
the presence of PMA (50 ng/ml)/ ionomycin (1 μM) for
12 hrs. Relative mRNA expression levels of Foxp3 of
GCSE treated samples were compared with control sam-
ple by qRT-PCR and protein level of Foxp3 was mea-
sured by flow cytometry.
Statistical analysis
A Student's t-test was used to calculate the statistical
significance of the experimental data. The level of sig-
nificance was set at *P < 0.05, **P < 0.01 and ***P < 0.001.
Significance was only indicated when appropriate.
Results
Analysis of marker substances in herbs by HPLC
To ensure the quality and purity of each preparation
of GCSE, HPLC analysis was performed by measuring
the content of known active compounds of the nine
marker substances of four herbs of GCSE by following
the Korean Pharmacopoeia Guidelines (9th edition).
Decursin, decursinol angelate and nodakenin in Angeli-
cae Gigantis Radix were quantified by HPLC-DAD using
a C18 column (YMC-Pack Pro, 4.6 × 250 mm, 5 μm)
and gradient elution with water and acetonitrile. The
amount of decursin, decursinol angelate, and nodakenin
in Angelicae Gigantis Radix were calculated as 4.22, 3.00
and 0.44%, respectively. The contents of marker sub-
stances in Coptidis Rhizoma (6.80% berberine), Glycyr-
rhizae Radix (3.04% glycyrrhizin, 0.87% liquiritigenin),
and Scutellariae Radix (15.80% baicalin, 0.10% baicalein,
0.04% wogonin) were calculated (Table 1 and Figure 1).These results indicate that the content of these nine
compounds in the GCSE showed the upper value of the
contents criterion in Korean Pharmacopoeia Guidelines
(9th edition).
Effect of GCSE treatment on T cells and B cells isolated
from AD-induced mice
Determination of optimal concentration of GCSE that
does not show cytotoxicity was performed using WST-1
assay. Treatment of GCSE to splenocytes for 72 hrs with
up to 1 mg/ml did not induce cell death (Figure 2A).
Based on this result, we used 0.25 mg/ml of GCSE or
each component of GCSE for all the in vitro experi-
ments. In in vivo AD condition, we examined the effect
of the GCSE treatment on the production of IgE by
CD19+ B cells isolated from AD-induced mice. Upon
LPS/IL-4 stimulation, GCSE treatment significantly re-
duced IgE production by B cells in a dose dependent
manner (Figure 2B). Then, we also evaluated the effect
of the GCSE treatment on the expression level of key
cytokines associated with the development of atopic
dermatitis. CD4+ T cells isolated from draining lymph
nodes of AD-induced mice were stimulated by PMA/
ionomycin for 4 hrs in the presence or absence of GCSE
(0.25 mg/ml) and the expression levels of cytokine genes
were analyzed by qRT-PCR. Treatment of GCSE signifi-
cantly decreased the expression levels of AD-associated
pathogenic cytokines (IL-4, IL-5, IL-13, INF-γ, IL-10,
IL-17 and TNF-α) (Figure 2C). In accordance with
mRNA result, treatment of GCSE also significantly
reduced the protein level of IL-4, IL-17 and IFN-γ in the
T cell culture supernatant (Figure 2D). Collectively, these
data indicate that treatment of GCSE could inhibit the
production of AD-associated pathogenic molecules pro-
duced by CD4+ T cells and IgE levels by CD19+ B cells.
Suppression of AD progression by topical
application of GCSE
Down-regulation of IgE production and pathogenic cyto-
kines by in vitro GCSE treatment led us to test whether
topical application of GCSE could also suppress the AD
progression. Experimental AD was induced on both ears
of BALB/c mice by alternating challenge with DNCB
and house dust mite extract [21,22]. AD symptoms in-
cluding erythema, horny substance, dryness, and swell-
ing were evidently seen in control group (Figure 3A).
However, treatment of GCSE (2 mg or 10 mg) signifi-
cantly reduced AD symptoms (Figure 3A). In agreement
with phenotypic observation, GCSE treatment signifi-
cantly decreased ear thickness (Figure 3B) as compared
with control treatment. Histological analysis further con-
firmed the therapeutic effect of GCSE. In correlation
with reduced thickness of epidermis, the numbers of in-








Figure 1 HPLC chromatograms of marker substances in individual herbs of Gami-Cheongyeul-Sodok-Eum (GCSE). HPLC analysis was
performed on YMC-Pack Pro C18 column (4.6 × 250 mm, 5 μm). The optimum mobile phase and wavelength for detection were acetonitrile and
water for (A) nodakenin, (B) decursin and (C) decursinol angelate (gradient, 20% - 80% ACN, 330 nm); (D) acetonitrile and water (3.4 g of
monobasic potassium phosphate and 1.7 g of sodium lauryl sulfate/1000 mL) for berberine (1:1, 345 nm); aqueous acetic acid and acetonitrile for (E)
glycyrrhizin (3:2, 254 nm) and (F) liquiritigenin (7.5:2.5, 276 nm); aqueous acetic acid and acetonitrile : methanol (7:3) for (G) baicalin, (H) baicalein, and
(I) wogonin (gradient, 25% - 52% ACN-MeOH, 277 nm). Data are representative of three independent experiments.
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trol group (Figure 3C). Since increased serum IgE level
is closely correlated with clinical symptoms of AD, we
tested whether improved AD symptom by GCSE treat-
ment is also related with changes in serum IgE levels.
In comparison with the control group, topical application
of GCSE significantly decreased IgE levels in the serum
(Cont; 80.4 μg/ml, GCSE-2 mg; 63.4 μg/ml, GCSE-10 mg;
44.5 μg/ml) (Figure 3D). To investigate whether GCSE
treatment could suppress IgE production by primary B
cells, CD19+ B cells isolated from the draining lymph
nodes of each treatment group were stimulated with LPS/
IL-4 for 72 hrs, then secreted IgE level was analyzed using
ELISA. As shown in Figure 3E, GCSE treatment signifi-
cantly reduced IgE expression (GCSE-2 mg; 72.7 ng/ml,
GCSE-10 mg; 40.2 ng/ml) as compared with the control
group (140.5 ng/ml). These results indicate that topical
treatment of GCSE decreases IgE production in the acti-
vated B cells.GCSE treatment suppresses the levels of pathogenic
cytokines
Dysregulated cytokine expression in CD4+ T cells medi-
ates the AD pathogenesis [12,23]. We tested whether
protective effect of GCSE treatment is also related with
changes in cytokine profiles. CD4+ T cells isolated from
draining lymph node of each treatment group were stim-
ulated with PMA/ionomycin. The levels of cytokines
were then compared between the groups. Treatment of
GCSE significantly reduced the expression levels both in
mRNA (Figure 4A) protein levels (Figure 4B) of patho-
genic cytokines such as IL-4, IL-5, IL-10, IL-13 and IL-17
in a dose dependent manner. These results suggest that
ameliorated AD symptoms by GCSE treatment is medi-
ated by down-regulation of pathogenic cytokines. Interest-
ingly, treatment of high dose of GCSE (10 mg) increased
Foxp3 expression (Figure 4A). GCSE treatment also re-
duced the expression levels of IL-4 and IL-13 in B cells as



























































































































Figure 2 Effect of GCSE treatment on T cells and B cells isolated from AD-induced mice. (A) Mouse splenocytes were incubated with
various concentrations of GCSE for 72 hrs. Cell viability was estimated with WST-1 assay. (B) Draining lymph node CD19+ B cells isolated from
AD-induced mice were stimulated with LPS (10 μg/ml)/IL-4 (5 ng/ml) in the presence of various concentrations of GCSE dissolved in 70% alcohol
for 72 hrs. Mouse IgE levels in the supernatant of B cell culture were measured by ELISA. Same volume of 70% alcohol was treated as control.
(C) Draining lymph node CD4+ T cells from AD-induced mice were stimulated with PMA (50 ng/ml)/ionomycin (1 μM) in the presence of GCSE
(0.25 mg/ml) for 4 hrs. Relative expression of cytokines of GCSE treated samples was compared with control samples by qRT-PCR. Expression level
of HPRT was used as an internal control. (D) CD4+ T cells from AD-induced mice were stimulated with PMA /ionomycin for 72 hrs in the presence
of GCSE (0.25 mg/ml), then protein level of each cytokine was analyzed by ELISA. Error bars indicate SD. One (*), two (**) and three (***) indicate

























































































Figure 3 Inhibition of AD progression by topical application of GCSE. (A) Representative ear pictures of control group or GCSE treated
groups were shown. (B) AD progression was assessed by measuring ear thickness, 24 hrs after each DNCB or mite extract treatment. (C) Ears
excised from each group were fixed with 4% paraformaldehyde for 24 hrs and embedded in paraffin. Paraffin embedded ears were sectioned
into 6 μm and stained with hematoxylin and eosin (H&E). Infiltration by lymphocytes and thickness of epidermis were observed under the
microscope (50X, 100X and 200X). (D) Total serum IgE levels were measured by ELISA, left. CD19+ B cells isolated from draining lymph node of
each group were stimulated with LPS (10 μg/ml)/IL-4 (5 ng/ml) for 72 hrs then IgE levels in the culture supernatant were measured by ELISA,
right. Error bars indicate SD. One (*), two (**) and three (***) indicate p < 0.05, p < 0.01 and p < 0.001 respectively. Data are representative of three
independent experiments.
































































































































Figure 4 Down-regulation of pathogenic cytokines by GCSE treatment. (A) Draining lymph node CD4+ T cells from each treatment group
were stimulated with PMA (50 ng/ml)/ionomycin (1 μM) for 4 hrs. Relative cytokine levels of GCSE treated samples were compared with control
samples by qRT-PCR. The expression level of HPRT was used as an internal control. (B) Draining lymph node CD4+ T cells from each group were
stimulated with PMA/ionomycin for 72 hrs, then, IL-4, IL-10, IL-17, and IFN-γ levels were measured by ELISA. (C) Draining lymph node CD19+ B
cells from each treatment group were stimulated for 4 hrs. Relative cytokine levels of GCSE treated samples were compared with control samples
by qRT-PCR. The expression level of HPRT was used as an internal control. Error bars indicate SD. One (*), two (**), and three (***) indicate p < 0.05,
p < 0.01 and p < 0.001 respectively. Data are representative of three independent experiments.
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over, reduction in IL-10 expression was observed in only
in GCSE-10 mg treated group (Figure 4C).
GCSE treatment increases Foxp3 expression in iTregs
In vivo treatment of GCSE to AD-induced mice
enhanced the Foxp3 expression in dLN CD4+ T cells
(Figure 4A). In order to verify the effect of GCSE to Treg
cells, we tested whether GCSE treatment could enhance
the Foxp3, a marker of regulatory T cells, expression in
in vitro differentiated inducible regulatory T cells (iTregs).
CD4+ T cells isolated from Foxp3-GFP knock-in mice
were cultured under iTreg differentiation condition [24]
for 3 days, then, stimulated with various concentrations of
GCSE in the presence of PMA/ionomycin for 12 hrs. As
shown in Figure 5A, treatment of GCSE to iTreg cells sig-
nificantly increased Foxp3 mRNA level in a dose-
dependent manner (0.1 mg/ml; 3.2 fold, 0.25 mg/ml; 5.1
fold). Consistent with mRNA level result, Foxp3 protein
level was also dose dependently up-regulated upon GCSE
treatment (0 mg/ml; 32%, 0.1 mg/ml; 52.7%, 0.25 mg/ml;
65.2%) (Figure 5B). These results suggest that inhibitory
effect of GCSE on the AD development could be mediated
by induction of Foxp3 in regulatory T cells.
Discussion
In this study, we identified a protective effect of GCSE
against experimental AD progression and elucidated theunderlying mechanism of action. Topical treatment of
GCSE significantly mitigated the pathogenic symptoms
of atopic dermatitis. GCSE treatment reduced serum IgE
level and secreted IgE level in activated B cells. GCSE
treatment also down-regulated the level of pathogenic
cytokines by B cells and CD4+ T cells of AD mice.
Recently, we have demonstrated that Taglisodog-eum
(TSE), a mixture of 11 herbs treatment, effectively sup-
pressed the development of experimental AD by down-
regulating pathogenic cytokines as well as IgE levels.
Underlying mechanism of TSE was mainly mediated by
reduction of NFκB (p65) transactivity in T cells and by
reduction of Aicda-mediated IgE class switching in B
cells [25]. Repeated treatment of TSE containing oint-
ment effectively improved the symptoms of AD patients
by reduction of SCORAD index as well as transepider-
mal water loss (TEWL) [26]. However TSE formula has
a side effect such as irritation upon ointment treatment.
Furthermore, it was very difficult to standardize the 11
complicated herbal extracts. To overcome those prob-
lems, we tested anti-atopic dermatitis effect of Gami-
Cheongyeul-Sodok-Eum (GCSE), a modified formula of
Cheongyeul-Sodok-Eum [16,17,27,28]. GCSE contains 9
kinds of oriental medicine extracts. Some components
of GCSE have anti-inflammatory and anti-allergic effects
[18-20,29,30]. Compared with each component of GCSE,
GCSE showed the most potent inhibitory effect on





























Figure 5 Up-regulation of Foxp3 expression in iTreg by GCSE treatment. CD4+ T cells isolated from the spleen and lymph node of 8 week
old Foxp3-GFP knock in mice were stimulated in a medium supplemented with anti-CD3 (1 μg/ml) / CD28 Ab (3 μg/ml), anti-IL-4 Ab (10 μg/ml),
anti-INF-γ Ab (10 μg/ml) and TGF-β (5 ng/ml) at day 1 and additional 50 U/ml rhIL-2 at day 3. Then iTreg cells were stimulated with various
concentrations of GCSE in the presence of PMA (50 ng/ml)/ ionomycin (1 μM) for 12 hrs. (A) Relative expression levels of Foxp3 of GCSE treated
samples were compared with control sample by qRT-PCR. Expression level of HPRT was used as an internal control. (B) GFP signal was measured
as protein level of Foxp3 by flow cytometry. Error bars indicate SD. One (*), two (**), and three (***) indicate p < 0.05, p < 0.01, and p < 0.001
respectively. Data are representative of three independent experiments.
Hwang et al. BMC Complementary and Alternative Medicine 2013, 13:312 Page 8 of 10
http://www.biomedcentral.com/1472-6882/13/312cytokine expression (Additional file 1: Figure S2 and
Additional file 2).
Based on these results, we tested the immunomodula-
tory effect of GCSE on experimental atopic dermatitis.
Several markers are employed to measure the severity
of clinical symptoms of experimental atopic dermatitis
including degree of scratching, pruritic skin lesion, and
levels of pathogenic cytokines including IL-4, IL-5, IL-13
and IFN-γ. Serum IgE level is considered as one of the
crucial markers of AD since about 70 ~ 80% of AD pa-
tients show significantly increased serum IgE level as
compared with non-AD patients [23,31,32]. Prior to per-
forming the ex vivo experiments with cells isolated from
AD-induced mice, we firstly characterized CD4+ T cells
and CD19+ B cells isolated from AD-induced mice by
comparing with cells isolated from normal mice. As
shown in Additional file 1: Figure S3, the expression
levels of AD-related pathogenic cytokines such as IL-4,
IL-5, IL-13, and IFN-γ in CD4+ T cells from AD-induced mice were significantly increased compared to
that of normal CD4+ T cells. When we measured secreted
IgE levels from CD19+ B cells, CD19+ B cells from AD-
induced mice produced much higher level of IgE com-
pared to that of normal mice. Next, we examined the
effect of GCSE on CD4+ T cells and CD19+ B cells iso-
lated from AD-induced mice. GCSE treatment signifi-
cantly reduced IgE production by primary CD19+ B cells
isolated from AD-induced mice (Figure 2B). GCSE treat-
ment also suppressed the expression of AD-related pa-
thogenic cytokines such as IL-4, IL-5, IL-13, IL-10, and
IL-17 in CD4+ T cells isolated from AD-induced mice
(Figure 2C-D). Topical application of GCSE significantly
reduced AD symptoms and ear thickness (Figure 3A-B)
and it significantly decreased tissue infiltration of lympho-
cytes (Figure 3C). On the aspect of B cells as an IgE pro-
ducer, it is quite notable that GCSE treatment significantly
reduced serum IgE levels (Figure 3D) as well as secretion
of IgE in the B cell culture supernatant in a dose-
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thought as a typical Th2 type immune disorder that ex-
presses high levels of Th2 type cytokines such as IL-4, IL-
5, and IL-13. However, recently, several groups suggested
that pro-inflammatory Th1 or Th17 type immune re-
sponses also play key roles in the maintenance of chronic
stage of AD [6,8,33]. IL-4, IL-5 and IL-13 are typical
Th2 type cytokines that stimulate Th2 differentiation
and IgE production by B cells [10,34]. IFN-γ is a typical
Th1 type cytokines that upregulates the expression of
CCL17 (TARC) and CCL22 (MDC), which recruit Th2
type cytokines to the inflamed site [35,36]. IL-17 coordi-
nates local tissue inflammation through upregulation of
pro-inflammatory cytokines (IL-6, TNF-α), neutrophil-
mobilizing cytokines (GM-CSF, MIP-2/CXCL2), chemo-
kines (MCP-1/CCL2, MIP-3α/CCL20) [37,38]. These
effector molecules collectively enable migration of acti-
vated T cells through extracellular matrix. Therefore,
down-regulation of Th1/Th17 and Th2 type of immune
responses is necessary to successfully modulate atopic
dramatis. In this aspect, it is quite notable that GCSE
treatment significantly down-regulated both Th2 cytokines
(IL-4, IL-5, IL-10, and IL-13) and Th1/Th17 type
pro-inflammatory cytokines such as IFN-γ and IL-17
(Figure 4A-B). High levels of IL-4 and IL-13 produced by
CD4+ T cells induce a class switching of plasma cells to
produce IgE [39,40]. IL-13 produced by B cells also plays a
crucial role in IgE production in an autocrine manner
[10]. Down-regulation of IL-4 and IL-13 by CD19+ B cells
(Figure 4C) and CD4+ T cells (Figure 4A) upon GCSE
treatment may cause the inhibition of the IgE production.
Furthermore, high concentration GCSE treatment (GCSE-
10 mg) increased Foxp3 expression. The forkhead family
protein Foxp3 is a transcription factor that is highly
expressed in CD4+ regulatory T cells (Tregs). Foxp3 is a
key regulator of T cell tolerance and plays a pivotal role
to the development and function of Tregs [41]. Interest-
ingly, addition of GCSE to iTreg cells significantly in-
creased mRNA as well as protein level of Foxp3 in a
dose-dependent manner (Figure 5). This result indicates
that GCSE may have a potential to generate iTregs.
However, further studies are required to identify the
exact component of GCSE that has iTreg inducing
activity.Conclusions
In conclusion, we have demonstrated that topical treat-
ment of GCSE ameliorated the progression of experi-
mental atopic dermatitis by reducing serum IgE and
AD-associated pathogenic cytokines levels while increas-
ing Foxp3 level. Our study collectively suggests the
beneficial effect of GCSE treatment in inhibiting the
progression of atopic dermatitis.Additional files
Additional file 1: Figure S1. Effect of GCSE and its components on IgE
production. Figure S2. Inhibitory effect of GCSE on cytokine production.
Figure S3. Characteristics of CD4+ T cells and CD19+ B cells from normal
and AD induced mice.
Additional file 2: Topical application of Gami-Cheongyeul-Sodok-
Eum (GCSE).
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